NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline

NCCN recently received $4 million in the form of two research grants from GlaxoSmithKline to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor, both promising therapies in the treatment of advanced melanoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarde...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news